Overview

Phenotropil (phenylpiracetam, fonturacetam, Phenylpiracetam, Carphedon) is a synthetic racetam-class compound created by adding a phenyl group to the 4-position of piracetam's pyrrolidone ring. It was developed in the 1980s at the Institute of Biomedical Problems of the Russian Academy of Sciences by Dr. Valentina Ivanovna Akhapkina, originally as part of the Soviet space program to enhance cosmonaut cognitive performance, stress resilience, and cold tolerance during extended space missions. The phenyl group addition dramatically increases lipophilicity and CNS bioavailability compared to piracetam, resulting in approximately 30–60 times greater potency and a pharmacological profile that uniquely combines nootropic, psychostimulant, anxiolytic, and physical performance-enhancing properties. Phenotropil was approved in Russia as a prescription nootropic (marketed as Phenotropil and later Nanotropil) and was subsequently banned by the World Anti-Doping Agency (WADA) after multiple doping violations in Olympic athletes.

The mechanism of action of phenotropil is multifaceted and not fully characterized, reflecting its broad receptor interaction profile. Like other racetams, it positively modulates AMPA-type glutamate receptors, enhancing excitatory neurotransmission and facilitating long-term potentiation — the synaptic basis of learning and memory. However, phenotropil additionally demonstrates significant dopaminergic activity: it increases dopamine receptor density (particularly D1 and D2/D3 subtypes) in the striatum, inhibits dopamine transporter (DAT)-mediated reuptake, and enhances dopaminergic neurotransmission in reward and motor circuits. This dopaminergic component underlies its stimulant properties — increased psychomotor speed, motivation, energy, and wakefulness — that distinguish it from the purely cognitive racetams. Additional mechanisms include GABA-A receptor modulation (contributing anxiolytic effects), nicotinic acetylcholine receptor activation, NMDA receptor modulation, and enhancement of cortical alpha and beta EEG activity. The remarkable cold-tolerance effect, which has been replicated in multiple rodent studies showing extended survival in hypothermic conditions, is thought to involve enhanced mitochondrial function and metabolic thermogenesis.

Phenotropil is typically dosed at 100–300 mg daily, taken in the morning or early afternoon to avoid insomnia. Its stimulant properties are often compared to modafinil, though with a faster onset (30–60 minutes), shorter duration (4–6 hours), and more pronounced eugeroic and motivational effects. Tolerance develops relatively quickly with daily use (typically within 1–2 weeks), necessitating cycling protocols — commonly 2–3 weeks on followed by 1–2 weeks off. Phenotropil stacks well with choline sources like alpha-GPC or CDP-choline for acetylcholine support, with L-theanine to smooth any stimulant edge, and with complementary racetams like oxiracetam or aniracetam for multi-pathway cognitive enhancement. Side effects may include insomnia, irritability, headache (especially without choline supplementation), increased blood pressure, and psychomotor agitation at higher doses. Due to its WADA-banned status, phenotropil is unsuitable for competitive athletes subject to anti-doping testing.

Mechanism of Action

Mechanism of Action

Phenotropil (also known as phenylpiracetam or fonturacetam) is a racetam derivative with a phenyl group added to the 4-position of the piracetam pyrrolidone ring. This structural modification dramatically increases lipophilicity, enhancing blood-brain barrier penetration by approximately 20-fold compared to piracetam, and introduces catecholaminergic activity absent in the parent compound.

Glutamatergic Enhancement

Like other racetams, phenotropil positively modulates AMPA receptors, the primary fast excitatory glutamate receptors. By slowing receptor desensitization kinetics, it prolongs excitatory postsynaptic potentials and facilitates long-term potentiation (LTP) in hippocampal and cortical circuits. This ampakine mechanism underlies the core nootropic effects shared with other racetam family members.

Catecholaminergic Stimulation

The phenyl group addition confers dopamine and norepinephrine reuptake inhibition that is unique among racetams. By blocking DAT and NET, phenotropil increases catecholamine levels in the prefrontal cortex, nucleus accumbens, and striatum. This mechanism produces the psychostimulant properties — enhanced alertness, motivation, physical stamina, and cold tolerance — that led to its ban by WADA as a performance-enhancing substance.

Cholinergic Modulation

Phenotropil enhances nicotinic acetylcholine receptor (nAChR) function, particularly at cortical α4β2 receptors involved in sustained attention and working memory. This cholinergic enhancement synergizes with glutamatergic potentiation to produce broad cognitive improvement.

Neuroprotective Properties

Phenotropil demonstrates anticonvulsant activity, likely through GABA system modulation, and provides neuroprotection against hypoxia, toxins, and ischemic injury. It increases neuronal membrane fluidity, which may improve receptor trafficking and synaptic transmission efficiency. These properties have supported its clinical use in Russia for stroke recovery and traumatic brain injury rehabilitation.

Reconstitution Calculator

Research

Safety Profile

Safety Profile: Phenotropil

Common Side Effects

• Insomnia and sleep disturbances (most common; dose-dependent; avoid evening dosing)
• Increased blood pressure and mild hypertension
• Psychomotor agitation and restlessness
• Headache
• Mild nausea and gastrointestinal discomfort
• Skin flushing and warmth sensation
• Irritability or emotional lability

Serious Adverse Effects

• Hypertensive crisis in predisposed individuals at high doses
• Severe insomnia with prolonged wakefulness
• Allergic reactions including skin rash and pruritus
• Potential for psychological dependence due to stimulant and mood-elevating effects
• Psychotic symptoms reported rarely at supratherapeutic doses
• Hepatotoxicity with chronic high-dose use (limited data)

Contraindications

• Known hypersensitivity to phenotropil or other racetam compounds
• Uncontrolled hypertension or severe cardiovascular disease
• Severe hepatic impairment
• Severe renal impairment
• Pregnancy and breastfeeding (no safety data)
• Panic disorder or severe anxiety disorders (stimulant effects may exacerbate)
• History of psychosis
• Children under 18 years

Drug Interactions

• Antihypertensives: May counteract blood pressure control; monitor closely
• CNS stimulants (caffeine, amphetamines, modafinil): Additive stimulatory effects; increased risk of hypertension, insomnia, and agitation
• Anticoagulants (warfarin): Some reports of altered coagulation parameters; monitor INR
• Antidepressants (SSRIs): Potential for additive activating effects; monitor for anxiety and agitation
• Other racetams: Additive cognitive effects; dose adjustment may be needed
• Antiepileptics: May alter seizure threshold; use with caution

Population-Specific Considerations

• Cognitive enhancement: Typical doses 100-200 mg once or twice daily; take in the morning or early afternoon to avoid insomnia
• Athletes: Banned by WADA as a stimulant; may cause positive doping test
• Hypertensive patients: Regular blood pressure monitoring essential; may require dose reduction
• Note: Phenotropil (fonturacetam) was developed in Russia and is the same compound as phenylpiracetam. It was originally approved for medical use in Russia but has been discontinued. Not approved by FDA or EMA.

Pharmacokinetic Profile